Corpus Intelligence IC Memo — BAPTIST HEALTH MEDICAL CENTER - LR 2026-04-26 04:04 UTC
IC Memo — BAPTIST HEALTH MEDICAL CENTER - LR
Investment Committee Memorandum | AR | 718 beds | Grade C | EBITDA uplift $48.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAPTIST HEALTH MEDICAL CENTER - LR

CCN 040114 | PULASKI, AR | 718 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAPTIST HEALTH MEDICAL CENTER - LR is a 718-bed suburban community hospital in PULASKI, AR with $652.8M in net patient revenue and a -5.4% operating margin. The hospital serves a payer mix of 27.4% Medicare, 10.0% Medicaid, and 62.6% commercial.

Thesis: Undervalued. Our ML models identify $48.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.4% to 1.9% (+736bps).

Net Revenue HCRIS$652.8M
Current EBITDA COMPUTED$-35.4M
Operating Margin COMPUTED-5.4%
Occupancy HCRIS66.4%
Revenue / Bed COMPUTED$909K
Net-to-Gross HCRIS24.6%
Distress Probability ML47.7%

2. Market Context & Competitive Position

108
AR Hospitals
-7.6%
State Median Margin
509
Comparable Hospitals

AR has 108 Medicare-certified hospitals with a median operating margin of -7.6%. The target's margin of -5.4% places it above the state median. Among 509 size-comparable peers (359-1436 beds), the median margin is -4.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (359-1436), prioritizing same-state peers. 509 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAPTIST HEALTH MEDICAL CENTER (Target)AR718$652.8M-5.4%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $48.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$13.7M+210bp18mo
Cost to Collect4.5%2.5%$13.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$12.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$7.9M+122bp9mo
Clean Claim Rate88.0%96.0%$418K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$13.7M
Cost to Collect
$13.1M
Denial Rate Reduction
$12.9M
A/R Days Reduction
$7.9M
Clean Claim Rate
$418K
Total EBITDA Uplift$48.1M
Current EBITDA$-35.4M
+ RCM Uplift+$48.1M
Pro Forma EBITDA$12.7M
Current Margin-5.4%
Pro Forma Margin1.9%
WC Released (1x)$25.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-54.4M$247.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-54.4M$254.2M0.00x-100.0%
Bull Case9.0x11.0x$-49.0M$395.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-49.0M$416.6M0.00x-100.0%
Bear Case11.0x10.0x$-59.9M$24.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-59.9M$7.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 509 hospitals with 359-1436 beds
  • Same-state prioritization (n=5)
  • Comp margins: P25=-15.2% / P50=-4.9% / P75=4.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.